Susquehanna International Group
CTXR icon

Susquehanna International Group’s Citius Pharmaceuticals CTXR Stock Holding History

Susquehanna International Group’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.2K Buy
36,838
+23,940
+186% +$19.3K ﹤0.01% 12743
2025
Q4 		$10K Sell
12,898
-35,288
-73% -$44.1K ﹤0.01% 12058
2025
Q3 		$59.8K Buy
48,186
+33,987
+239% +$47.4K ﹤0.01% 11801
2025
Q2 		$22.6K Buy
+14,199
New +$13K ﹤0.01% 12311
2024
Q4 		– Sell
-6,603
Closed -$44.5K – 12339
2024
Q3 		$82.6K Sell
6,603
-19,019
-74% -$320K ﹤0.01% 11160
2024
Q2 		$374K Buy
25,622
+25,173
+5,606% +$451K ﹤0.01% 8965
2024
Q1 		$10.1K Sell
449
-5,191
-92% -$94.8K ﹤0.01% 11908
2023
Q4 		$107K Buy
5,640
+3,660
+185% +$69.4K ﹤0.01% 11272
2023
Q3 		$33.9K Sell
1,980
-4,029
-67% -$95.8K ﹤0.01% 11442
2023
Q2 		$180K Sell
6,009
-12,371
-67% -$407K ﹤0.01% 10390
2023
Q1 		$538K Buy
18,380
+5,208
+40% +$150K ﹤0.01% 8403
2022
Q4 		$260K Buy
13,172
+10,985
+502% +$300K ﹤0.01% 9451
2022
Q3 		$66K Sell
2,187
-4,848
-69% -$133K ﹤0.01% 12018
2022
Q2 		$162K Buy
7,035
+1,644
+30% +$45.1K ﹤0.01% 10926
2022
Q1 		$241K Sell
5,391
-1,968
-27% -$77.7K ﹤0.01% 10791
2021
Q4 		$283K Sell
7,359
-3,285
-31% -$149K ﹤0.01% 10623
2021
Q3 		$540K Buy
10,644
+2,351
+28% +$118K ﹤0.01% 9179
2021
Q2 		$721K Buy
8,293
+4,370
+111% +$263K ﹤0.01% 8670
2021
Q1 		$175K Buy
+3,923
New +$156K ﹤0.01% 11532
2020
Q1 		– Sell
-971
Closed -$25K – 10303
2019
Q4 		$25K Buy
+971
New +$14.2K ﹤0.01% 9462

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's CTXR Position: Q1 2026 in Review

Susquehanna International Group increased its Citius Pharmaceuticals (CTXR) stake by 186% in Q1 2026, buying an estimated $19.3K and bringing the position to 36,838 shares worth $33.2K. The position accounts for ﹤0.01% of the portfolio, ranked #12743.

Susquehanna International Group first reported a position in CTXR in Q4 2019 and has held it in 20 quarters since. The position peaked at $721K in Q2 2021. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • Susquehanna International Group held 36,838 shares of Citius Pharmaceuticals worth $33.2K as of Q1 2026.
  • Susquehanna International Group bought 23,940 Citius Pharmaceuticals shares in Q1 2026, an estimated $19.3K.
  • Citius Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12743 holding.
  • Susquehanna International Group first reported a position in Citius Pharmaceuticals in Q4 2019 and has held it in 20 quarters since.
  • Susquehanna International Group's Citius Pharmaceuticals position peaked at $721K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.